01241nam0M2200385--I450-99000278299020331620091118114707.0029784881X000278299USA01000278299(ALEPH)000278299USA0100027829920060718d2004----||itac50 baengGB||||||||001yy<<The >> age of ShakespeareFrank KermodeLondonWeidenfeld & Nicolson2004194 p.ill.21 cm20012001001-------2001KERMODE,Frank159998ITICCUISBD20051009Mediateche del Politecnico della cultura, delle arti, delle lingue della Fondazione Scuole civiche milanesi Milano MIMI1223SCMSCServizio biblioteca di storia dell'arte dell'Università degli studi di Parma Parma PRPR0174PARSS990002782990203316II.2.B.4557259 DSLLBKDSLLDSLL11020060718USA010923DSLL9020091118USA011014DSLL9020091118USA011147Age of Shakespeare996422UNISA03626nam 22007691 450 991095456130332120120628124337.09786613851970978184731909818473190929781474200776147420077X978128353952412835395279781847319081184731908410.5040/9781474200776(CKB)2560000000090539(EBL)990457(OCoLC)805517578(SSID)ssj0000701503(PQKBManifestationID)12261547(PQKBTitleCode)TC0000701503(PQKBWorkID)10676040(PQKB)11509513(MiAaPQ)EBC1772924(MiAaPQ)EBC990457(Au-PeEL)EBL1772924(CaPaEBR)ebr10589790(CaONFJC)MIL385197(OCoLC)893332401(OCoLC)809536917(UtOrBLW)bpp09259369(MiAaPQ)EBC6164402(Au-PeEL)EBL990457(UtOrBLW)BP9781474200776BC(Perlego)875645(EXLCZ)99256000000009053920150827d2012 uy 0engur|n|---|||||txtccrLaw and the regulation of medicines /Emily Jackson1st ed.Oxford ;Portland, Ore. :Hart Publishing,2012.1 online resource (308 p.)Description based upon print version of record.9781849461795 1849461791 Includes bibliographical references (pages 267-292).What are medicines and why are they special? -- Clinical trials -- Licensing -- Pharmacovigilance and liability for dangerous drugs -- Marketing -- Funding and access to medicines in the UK -- Funding and access to medicines : a global problem -- The future of medicines I : pharmacogenetics -- The future of medicines II : enhancement."The principal purpose of this book is to tell the story of a medicine's journey through the regulatory system in the UK, from defining what counts as a medicine, through clinical trials, licensing, pharmacovigilance, marketing and funding. The question of global access to medicines is addressed because of its political importance, and because it offers a particularly stark illustration of the consequences of classifying medicines as a private rather than a public good. Two further specific challenges to the future of medicine's regulation are examined separately: first, pharmacogenetics, or the genetic targeting of medicines to subgroups of patients, and second, the possibility of using medicines to enhance well-being or performance, rather than treat disease. Throughout, the emphasis is on the role of regulation in shaping and influencing the operation of the medicines industry, an issue that is of central importance to the promotion of public health and the fair and equitable distribution of healthcare resources."--Bloomsbury Publishing.DrugsLaw and legislationGreat BritainPharmacyLaw and legislationGreat BritainMedical & healthcare lawDrugsLaw and legislationPharmacyLaw and legislation344.410416Jackson Emily1966-1496592UtOrBLWUtOrBLWBOOK9910954561303321Law and the regulation of medicines4474853UNINA